Find a clinical trial


Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Treatments-177lu-edotreotide prrt, everolimus, amino-acid solution
Phase-phase 3
Start date-February 2017
Condition-neuroendocrine tumours
Targets-mTOR, FKBP-12
Countries-Australia, Austria, France, Germany, and 5 other countries

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Phase-phase 1/phase 2
Start date-December 2016
Conditions neuroendocrine tumours, carcinoma, small cell lung, neuroendocrine carcinoma
US States
Massachusetts, New York, Tennessee, and Texas
Countries-United Kingdom

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in NETs

Treatment -satoreotide tetraxetan
Phase-phase 1/phase 2
Start date-March 2017
Condition-neuroendocrine tumours
Countries-Australia, Austria, Denmark, France, Switzerland, and United Kingdom

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Phase-phase 2
Start date-November 2015
Condition-neuroendocrine tumour
Countries-Belgium, Denmark, France, Germany, and 6 other countries

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Phase-phase 2
Start date-December 2015
Conditions-mesothelioma, thyroid cancer, anal cancer, bile duct cancer, cervical cancer, endometrial cancer, gallbladder cancer, salivary gland cancer, small cell lung cancer, vulvar cancer, solid tumour, neuroendocrine tumour
US States-California, Colorado, Florida, Illinois, and 8 other states
Australia, Brazil, Canada, Colombia, and 16 other countries
Tags-immunotherapy, metastatic cancer, microsatellite instability

Post-Authorization Long-Term Safety Study of LUTATHERA

Start date-November 2018
Condition-neuroendocrine tumours
Countries-United Kingdom

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Phase-phase 2
Start date-November 2015
Conditions-brain tumour, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, sarcoma, ovarian cancer, non-small cell lung cancer, papillary renal cell carcinoma, thyroid cancer, bile duct cancer, salivary gland cancer, carcinoid, solid tumour, anaplastic large cell lymphoma, neuroendocrine tumour
US States
Arizona, California, Colorado, Connecticut, and 22 other states
Countries -Australia, France, Germany, Hong Kong, and 9 other countries

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET

Status -recruiting

Treatment drug: everolimus, stz-5fu

Phase -phase 3

Start date -October 2014

Condition -neuroendocrine tumours

Countries -Denmark, France, Germany, Italy, and 4 other countries


There is no established treatment option for patients with a diagnosis of poorly differentiated (faster growing) neuroendocrine carcinoma (NEC) that started in the gastrointestinal tract, that has spread, and whose disease has not responded to treatment with a chemotherapy called a platinum, in addition to etoposide. 

The goal of NET-02 will be to determine if one of the treatment options delays growth (progression) of the disease, more than the other.

This study will open in approximately 16 centres around the United Kingdom and will be co-ordinated through The Christie NHS Foundation Trust in Manchester, the University of Manchester and the Leeds Clinical Trials unit. Chief Investigator: Dr Mairéad McNamara


You can find out more about current UK NET trials by following these links:


Find trials around the world

Click on the link below for a database of privately and publicly funded clinical studies conducted in the UK and around the world. 

The only crowd-funded cancer drug trial in history

The team at Uppsala University have prepared the above video update on the AdVince phase 1 clinical trial for neuroendocrine tumour.

“A total of twelve patients will have to be treated at different dose levels. So far five patients have been treated and there are still seven patients to go, ” says Prof Magnus Essand.

“The first patient was treated in March 2016 so we hope that we can now finish the next seven in the next two years from now.

“Phase1 trial is about safety data primarily, that is the primary endpoint. But of course, we are also looking at efficacy if there are response.

“And we have seen responses already at the lower dosages we have seen occasions of tumour shrinkage in the liver that has been treated.

“So it is promising but before we say anything conclusive we need to finish the phase1 trial and we need to treat even more patients before we can make any firm conclusions. So it is very early days.”

Completed Studies 

A list of recent published trials with links to data.

Research publications from the NET Patient Foundation

In house research from the NET patient Foundation 

NET Patient Foundation funded research publications

Pilot NET cancer research projects made possible through your support via the NET Patient Foundation grant.